- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02510768
A Study to Evaluate the Efficacy of ELAPR in Women With Striae Distensae Alba
June 28, 2018 updated by: Elastagen Pty Ltd
A Randomized, Within-Subject, Placebo-Controlled, Single-Blind Study to Evaluate the Efficacy of ELAPR002f and ELAPR002g in Women With Striae Distensae (SD) Alba
The study is designed to evaluate the efficacy of two formulations of a cross-linked tropoelastin matrix given the product codes ELAPR002f and ELAPR002g (collectively referred to as ELAPR or ELAPR002) for the treatment of Striae Distensae (SD) alba when administered as intradermal implants.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The study will consist of six study visits.
There will be a screening visit to confirm eligibility and to assess baseline parameters (Day -28 to Day -1).
For enrolled subjects there will be three intradermal (i.d.) treatment sessions of ELAPR002f or ELAPR002g and placebo, given at one-monthly intervals (approximately Day 0, Day 28 and Day 56).
There will be a safety assessment visit 7 days after the first treatment session (Day 7) to review any adverse events and assess the implant sites.
ELAPR002f or ELAPR002g will be administered alone vs. placebo.
Subjects will be followed for a total of 12 weeks (to Day 84) following the first treatment, with efficacy and safety assessments undertaken at each study visit.
At the final follow-up visit (Day 84) a biopsy sample will be taken from each of the treated SDs (active and placebo treated), together with a control biopsy of normal skin collected from an area of the lateral aspect of the abdomen, hip or thigh without an SD alba.
Each study subject will act as their own control with active and placebo treatments given single-blind to contralateral sides of the abdomen, hip or thigh, into matched and paired SD.
Prior to administration the selected injection sites along the length of SD alba to be treated will be identified and marked with a semi-permanent mark to ensure consistency of anatomic sites for treatment and biopsy.
Follow-up period extended to D168, D336 and D504.
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
London, United Kingdom, NW10 7EW
- Hammersmith Medicines Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
28 years to 53 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Female subjects with at least four abdominal, hip or thigh SD alba which are approximately bilaterally symmetrical (similar dimensions/location/colour) and are of at least 6 cm in length and no more than 5mm wide.
- SD alba within an area of skin of otherwise normal, smooth, mainly flat appearance.
- Age: 30 - 55 years.
- BMI: 18.5 to 35.0 Kg/m2.
- Capable of providing voluntary informed consent.
- Good general health.
- Female subjects who are sexually active will be of non-child bearing potential (i.e., surgically sterilized or postmenopausal), abstain from sexual intercourse, or use a reliable method of contraception (e.g. hormonal contraceptive, condom, IUD) for at least 30 days prior to dosing and during the duration of the study.
- Fitzpatrick skin types II, III or IV.
Exclusion Criteria:
- SD alba within an area of otherwise abnormal skin appearance including unusual lumpiness or abnormal skin laxity.
- Current or previous medical or surgical treatment of SD.
- Known hypersensitivity to tropoelastin, hyaluronic acid or any other component of ELAPR002f or ELAPR002g.
- Female subjects with a positive pregnancy test, women refusing to agree to adequate contraception and pregnancy tests during the study, or women who are planning to become pregnant during the period of the trial.
- Participation in a clinical trial of a pharmacological agent within 1 month prior to screening.
- Clinically significant haematology or biochemistry findings at screening.
- Positive test for hepatitis B, hepatitis C or HIV at screening.
- Bleeding diathesis, anticoagulant drugs, thrombocytopenia or clinically significant prolonged activated partial thromboplastin time (APTT) or prothrombin time (PT).
- Chronic use of aspirin, other non-steroidal anti-inflammatory drugs or other anti-platelet agents.
- History of keloid formation.
- Systemic corticosteroids within last 12 weeks.
- Diabetes or other metabolic disorders that may interfere with the subject's response to treatment in the opinion of the investigator.
- Any serious medical condition which in the opinion of the investigator would have a strong possibility of requiring systemic corticosteroid medication.
- Females who are pregnant or lactating.
- Previous administration of tropoelastin.
- A history of anaphylaxis or allergic reactions including any known hypersensitivity to lidocaine.
- Use of any investigational product on the intended implant site in the previous 12 months.
- Fitzpatrick skin types I, V or VI.
- Any other factor that in the opinion of the Investigator would make the subject unsafe or unsuitable for the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Saline
|
Intradermal implant
|
Experimental: ELAPR002f
ELAPR002f A tropoelastin polymer cross-linked with hyaluronic acid.
|
Intradermal implant
|
Experimental: ELAPR002g
ELAPR002g A tropoelastin polymer cross-linked with hyaluronic acid.
|
Intradermal implant
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Size of SD alba scars pre and post treatment.
Time Frame: 3 months
|
Measurement of scar dimensions pre and post treatment (width x length x depth in mm) as measured by 3D photography, also 2D photography, subject satisfaction and biopsy (histology).
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency and severity of implant site reactions post treatment.
Time Frame: 3 months
|
Measure incidence and severity of implant site reactions as assessed by clinical observation and subject diary card records.
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 16, 2015
Primary Completion (Actual)
October 3, 2017
Study Completion (Actual)
March 6, 2018
Study Registration Dates
First Submitted
July 26, 2015
First Submitted That Met QC Criteria
July 27, 2015
First Posted (Estimate)
July 29, 2015
Study Record Updates
Last Update Posted (Actual)
July 2, 2018
Last Update Submitted That Met QC Criteria
June 28, 2018
Last Verified
June 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ELAPR-P1C
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Striae Distensae
-
First Affiliated Hospital of Jinan UniversityScience and Technology Program of Guangzhou,Guangzhou Sipintang Biological...UnknownTreatments of Striae DistensaeChina
-
Kasr El Aini HospitalCompleted
-
First Affiliated Hospital of Jinan UniversityScience and Technology Program of GuangzhouUnknownTreatments of Striae GravidarumChina
-
Jose R. Reyes Memorial Medical CenterCompletedStriae GravidarumPhilippines
-
Shahid Beheshti University of Medical SciencesCompletedExcimer Laser | White StriaeIran, Islamic Republic of
-
Al-Azhar UniversityRecruiting
-
American University of Beirut Medical CenterWellcome TrustCompleted
-
Brazilan Center for Studies in DermatologyCompletedTreatment | Striae | Stretch MarksBrazil
-
Candela FranceCompleted
-
Mahidol UniversityUnknown
Clinical Trials on ELAPR002f
-
AbbVieRecruiting
-
AbbVieRecruitingAtrophic Acne ScarsCanada, Germany
-
Elastagen Pty LtdCompletedAtrophic Acne ScarUnited Kingdom